Interestingly, when toripalimab was administrated two days after chemotherapy rather than being used simultaneously, the combinational neoadjuvant regime showed a trend toward a higher pCR rate (36.4%, 4/11 versus 7.7%, 1/13, P = 0.079) ( 60 ).
Moreover, the percentages of monocytes ( Figure 6C ) remained similar in Rs and NRs from baseline through day 3, then followed by a rapid elevation on day 7 in NRs with near significance ( p = 0.079).
We found a significant association between the activating combinations KIR2DS1/HLAC2C2-C1C2 with the TTF > 10 months ( p = 0.002) and a statistical trend within KIR3DS1/HLABw4w4-w4w6 with the TTF > 10 months ( p = 0.079).
We also found an increase in CD11b + granulocytes (mean difference: 11.82, 95% CI: 0.207 – 23.43, two-tailed t-test p=0.0475) in GM-CSF-treated mice ( Figure 3D , Supplementary Figure S2D ), which was generally accompanied by a strong trend toward increased neutrophils (mean difference: 13.85, 95% CI: -2.555 – 30.26, two-tailed t-test p=0.079) vs placebo-treated mice ( Figure 3E , Supplementary Figure S2E ).
Total adipose tissue (TAT) showed a near-significant trend (OR = 1.01, 95% CI: 0.99-1.02, p = 0.080), indicating a potential but non-significant association ( Table 2 ).
However, the survival disadvantage associated with high NTRK1 was statistically significant in females (p=0.005) but only showed a trend in males (p=0.08), likely due to the smaller sample size of the male cohort.
Older subjects showed higher risks for musculoskeletal pain (panel B, increased risk in age groups 6-17 years, p-value = 0.02), cardiovascular symptoms (panel E, significantly higher in the 12-17 years age group, p-value = 0.003) and, with borderline significance, for sleep disorders (panel A, p=0.08) and sensory symptoms (panel F, p=0.05).
LS greater than 6 Kpa at day +14 also showed a trend toward worse OS (asHR: 2.3, 95% CI 0.9–6.0; p=0.08).
One month after the third and fourth dose, the levels were 226 BAU/ml (IQR: 7.0; 294 BAU/ml) and 433 BAU/ml (IQR: 326; 798 BAU/ml) with the increase being borderline significant (193 BAU/ml, 95% CI: −22; 569 BAU/ml, p = 0.080).
Patients developing ABMR during follow-up showed a trend towards higher amino acid MM (88±5 vs. 63±22, p=0.08); global PIRCHE-II (117±48 vs. 80±38, p=0.06) and higher eplet MM load (41.5±7 vs. 32±11, p=0.07).
Although both subgroups showed significant 2-year OS advantage, the subgroups difference tended towards significance (p=0.08) ( Supplementary Figure 5C ).
Significantly decreased levels of the MoAM associated chemokines CCL2 and CCL7 (21% and 69%, respectively) and a strong trend towards decreased total BALF macrophage counts (30% decrease on average, p = 0.08) in treated animals further corroborates the anti-inflammatory effect of the IRAK4 inhibitor ( Figures 8B, C ).
Furthermore, CXCL12 showed a trend towards a shorter PFS (HR=2.30; 95% CI 0.86-5.97; p=0.08) in male patients.
IL-1α levels showed a statistical trend for association with low IP (p-value=0.08) ( Figure 3E ) and was significantly increased in infants with less abx (p-value < 0.01) ( Figure 3F ), more MOM feed (p-value <0.05) ( Figure 3G ), and later GA (p-value < 0.01) ( Figure 3H ).
The results indicated a marginally significant difference in HER2+ between the low-to-intermediate and high-to-very-high-risk groups ( p = 0.08), with a significant difference observed within subcategories ( p < 0.05).
Although iNOS expression was marginally insignificant between Adv/GM-CSF treated and untreated tumors (p = 0.08).
As compared to smokers, non-smokers showed borderline significant higher CRP using morning ( p =0.08) and evening ( p =0.05) saliva.
Results revealed a clear trend toward a high diversity of microbial species when examining the above-mentioned consecutive samples ( p = 0.08).
CeMV seropositive dolphins had a marginally significant reduction in the absolute number of CD4+ helper T cells ( p = 0.08).
Moreover, in GDM-HBC a higher percentage of cells was positive for M1 markers CD80 and CD40, but these increases did not reach significance (Table 3 ); however, the M1 marker CD86 (Figures 4 D,H) showed a trend toward increased levels in GDM ( p = 0.08; Table 3 ).
The second and third ranked DMRs predicted by smoking reached borderline significance, p < 0.08 (Table 1 ; Table S1 in Supplementary Material).
IL-6 showed a marginal trend (log 2 FC = -0.619, p = 0.080).
A favorable trend in PFS was also observed (P = 0.08; HR = 0.62, 95% CI: 0.36–1.07) ( Supplementary Figure 2A ).
The etiology of infertility showed a trend toward significance (p=0.08).
Sensitivity also showed a trend toward superiority for DL (0.77 vs 0.68, P = 0.08).